Robert W Carlson

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Treatment of breast cancer in countries with limited resources
    Robert W Carlson
    Department of Medicine, Stanford University, Stanford, California 94305, USA
    Breast J 9:S67-74. 2003
  2. pmc A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W Carlson
    Eastern Cooperative Oncology Group, Boston, MA, USA
    Breast Cancer Res Treat 133:1049-56. 2012
  3. ncbi request reprint The history and mechanism of action of fulvestrant
    Robert W Carlson
    Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Breast Cancer 6:S5-8. 2005
  4. ncbi request reprint Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations
    Robert W Carlson
    Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 4:971-9. 2006
  5. ncbi request reprint Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women
    Robert W Carlson
    Stanford Cancer Center, Stanford University, Stanford, CA 94305, USA
    J Clin Oncol 28:3917-21. 2010
  6. ncbi request reprint A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group
    Robert W Carlson
    Stanford University, Stanford, California 94305 5826, USA
    Cancer Invest 24:677-81. 2006
  7. ncbi request reprint Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer
    Tiffany H Svahn
    Division of Oncology, Stanford University, Stanford, California 94305, USA
    J Natl Compr Canc Netw 7:115-21. 2009
  8. ncbi request reprint NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
  9. ncbi request reprint Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Cathie T Chung
    Division of Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:S18-23. 2004
  10. ncbi request reprint Predictors of local recurrence after breast-conservation therapy
    Kathleen C Horst
    Department of Radiation Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:425-38. 2005

Detail Information

Publications51

  1. ncbi request reprint Treatment of breast cancer in countries with limited resources
    Robert W Carlson
    Department of Medicine, Stanford University, Stanford, California 94305, USA
    Breast J 9:S67-74. 2003
    ..Efforts to reduce the number of breast cancers diagnosed at an advanced stage thus have the potential to improve rates of survival while decreasing the use of limited resources...
  2. pmc A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W Carlson
    Eastern Cooperative Oncology Group, Boston, MA, USA
    Breast Cancer Res Treat 133:1049-56. 2012
    ..Further studies of EGFR inhibition plus endocrine therapy do not appear warranted, but if performed should include attempts to identify biomarkers predictive of antitumor activity...
  3. ncbi request reprint The history and mechanism of action of fulvestrant
    Robert W Carlson
    Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    Clin Breast Cancer 6:S5-8. 2005
    ..Methods of exploiting the interactions between these nonsteroidal hormone-dependent mechanisms of resistance and hormonal agents such as fulvestrant are an active area for drug development and clinical investigation...
  4. ncbi request reprint Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations
    Robert W Carlson
    Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 4:971-9. 2006
    ....
  5. ncbi request reprint Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women
    Robert W Carlson
    Stanford Cancer Center, Stanford University, Stanford, CA 94305, USA
    J Clin Oncol 28:3917-21. 2010
    ....
  6. ncbi request reprint A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group
    Robert W Carlson
    Stanford University, Stanford, California 94305 5826, USA
    Cancer Invest 24:677-81. 2006
    ..To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer...
  7. ncbi request reprint Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer
    Tiffany H Svahn
    Division of Oncology, Stanford University, Stanford, California 94305, USA
    J Natl Compr Canc Netw 7:115-21. 2009
    ..Adjuvant aromatase inhibitor use increased after the first report of ATAC, with this increase associated with older age, vascular disease, overexpression of HER2, or more advanced stage. Substantial variation was seen among institutions...
  8. ncbi request reprint NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
    ..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting...
  9. ncbi request reprint Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Cathie T Chung
    Division of Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:S18-23. 2004
    ..There is now substantial medical evidence supporting the use of AIs in postmenopausal women with early-stage, HR-positive breast cancer...
  10. ncbi request reprint Predictors of local recurrence after breast-conservation therapy
    Kathleen C Horst
    Department of Radiation Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:425-38. 2005
    ..The ability to predict for an increased risk of ipsilateral breast tumor recurrence enhances the ability to select optimal local treatment strategies for women considering BCT...
  11. ncbi request reprint Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
    Robert W Carlson
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003
    ....
  12. ncbi request reprint High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer
    Robert W Carlson
    Stanford University, Stanford, CA, USA
    Cancer Treat Rev 30:131-7. 2004
  13. ncbi request reprint Rational surveillance programs for early stage breast cancer patients after primary treatment
    Joseph A Mollick
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA 94305, USA
    Breast Dis 21:47-54. 2004
    ....
  14. ncbi request reprint The role of aromatase inhibitors in early breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, 300 Pasteur Drive, H0274, Stanford, CA 94305, USA
    Curr Treat Options Oncol 4:133-40. 2003
    ..New AIs may challenge the position of tamoxifen as the gold standard for the treatment of early stage breast cancer in postmenopausal women...
  15. ncbi request reprint Update: NCCN breast cancer Clinical Practice Guidelines
    Robert W Carlson
    Division of Medical Oncology, Stanford Hospital and Clinics, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2236, Stanford, CA 94305 5826, USA
    J Natl Compr Canc Netw 3:S7-11. 2005
  16. pmc Impaired interferon signaling is a common immune defect in human cancer
    Rebecca J Critchley-Thorne
    Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 106:9010-5. 2009
    ....
  17. pmc Selecting high priority quality measures for breast cancer quality improvement
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Med Care 46:762-70. 2008
    ..We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population...
  18. pmc Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
    Ashley A Powell
    Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 7:e33788. 2012
    ..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery...
  19. ncbi request reprint Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:3525-33. 2007
    ..To assess the spectrum and reversibility of the cardiotoxicity observed in the adjuvant trastuzumab trials...
  20. ncbi request reprint Predictors of reexcision findings and recurrence after breast conservation
    Melanie C Smitt
    Department of Radiation Oncology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 57:979-85. 2003
    ..To identify predictors of reexcision findings and local recurrence in the setting of breast-conserving therapy with radiation...
  21. doi request reprint First-line chemotherapy for metastatic breast cancer
    Melinda L Telli
    Department of Medicine, Division of Medical Oncology, Stanford University, CA, USA
    Clin Breast Cancer 9:S66-72. 2009
    ....
  22. ncbi request reprint Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer
    Anne Renee Hartman
    Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
    Breast Cancer Res Treat 82:61-9. 2003
    ..To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer...
  23. ncbi request reprint Clathrate hydrates of oxidants in the ice shell of Europa
    Kevin P Hand
    Department of Geological and Environmental Sciences, Stanford University, Stanford, California 94305, USA
    Astrobiology 6:463-82. 2006
    ..Clathrate-sealed, gas-filled bubbles in the near surface ice could also provide an effective trapping mechanism, though they cannot explain the 5771 A (O2)2 absorption...
  24. doi request reprint Energy, chemical disequilibrium, and geological constraints on Europa
    Kevin P Hand
    Department of Geological and Environmental Sciences, Stanford University, Stanford, California, USA
    Astrobiology 7:1006-22. 2007
    ..Such an ocean would be energetically hospitable for terrestrial marine macrofauna. The availability of reductants could be the limiting factor for biologically useful chemical energy on Europa...
  25. pmc Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
    Holbrook E Kohrt
    Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA
    J Clin Invest 122:1066-75. 2012
    ....
  26. pmc New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients
    Holbrook E Kohrt
    Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
    BMC Cancer 8:66. 2008
    ..Our goal was to develop new models to quantify the risk of NSLN metastasis in SLN-positive patients and to compare predictive capabilities to another widely used model...
  27. ncbi request reprint Goals and objectives in the management of metastatic breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, Stanford, California, USA
    Oncologist 8:514-20. 2003
    ..Both physician and patient perspectives are important in establishing the objectives of treatment, and this process is optimally an interactive and ongoing process throughout the course of disease...
  28. ncbi request reprint NCCN breast cancer clinical practice guidelines in oncology: an update
    Robert W Carlson
    Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, California, USA
    J Natl Compr Canc Netw 1:S61-3. 2003
    ..The new guidelines for axillary lymph node staging are reported on in a companion article in this issue...
  29. pmc Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Geoffrey J Yoon
    Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA
    J Am Coll Cardiol 56:1644-50. 2010
    ....
  30. ncbi request reprint mTOR inhibitors in the treatment of breast cancer
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94035 5826, USA
    Oncology (Williston Park) 27:38-44, 46, 48 passim. 2013
    ..This review will summarize results of preclinical and clinical studies aswell as ongoing clinical trials with mTOR or dual PI3K/mTOR inhibitors...
  31. ncbi request reprint The decline in breast cancer incidence: real or imaginary?
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Curr Oncol Rep 11:21-8. 2009
    ..However, significant controversy remains as to the timing, causes, generalizability, and longevity of this reported decline in incidence...
  32. ncbi request reprint Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial
    David Spiegel
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5718, USA
    Cancer 110:1130-8. 2007
    ..Subsequent findings concerning the question of whether such psychosocial support affects survival have been mixed...
  33. ncbi request reprint Phyllodes tumors of the breast: natural history, diagnosis, and treatment
    Melinda L Telli
    Department of Medicine, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 5:324-30. 2007
    ..Adjuvant systemic therapy is of no proven value. Patients with locally recurrent disease should undergo wide excision of the recurrence with or without subsequent radiotherapy...
  34. ncbi request reprint Sequencing of endocrine therapies in breast cancer--integration of recent data
    Robert W Carlson
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    Breast Cancer Res Treat 75:S27-32; discussion S33-5. 2002
    ..The establishment of the optimal sequence of the endocrine therapies should offer significant benefits to women with hormone-sensitive metastatic breast cancer...
  35. ncbi request reprint Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Cancer Center 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
    Gynecol Oncol 102:508-12. 2006
    ..To analyze corpus cancer patients with a breast cancer history for risk of developing aggressive uterine histologic types...
  36. ncbi request reprint Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer
    Ruth M O'Regan
    Hematology Oncology, Emory University School of Medicine, Translational Breast Cancer Research Program, Winship Cancer Institute, Atlanta, GA, USA
    Clin Breast Cancer 6:163-8. 2005
    ..The objective of this study was to determine the pCR rate in patients with stage III breast cancer treated with 4 cycles of TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2) on day 1 before surgery...
  37. ncbi request reprint A roundtable discussion of aromatase inhibitors as therapy for breast cancer
    D Craig Allred
    Baylor College of Medicine, Houston, Texas, USA
    Breast J 9:213-22. 2003
    ..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease...
  38. ncbi request reprint Breast cancer
    Robert W Carlson
    Stanford Hospital and Clinics, USA
    J Natl Compr Canc Netw 3:238-89. 2005
  39. ncbi request reprint Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines
    Benjamin O Anderson
    Department of Surgery, University of Washington, Seattle, 98195, USA
    Breast J 12:S3-15. 2006
    ..Future research is needed to better determine how these guidelines can best be implemented in limited-resource settings...
  40. ncbi request reprint Overview of breast health care guidelines for countries with limited resources
    Benjamin O Anderson
    Department of Surgery, University of Washington, Seattle, Washington 98195, USA
    Breast J 9:S42-50. 2003
    ..The panels' findings outline specific steps for prioritizing the use of limited resources to decrease the impact of breast cancer around the globe...
  41. ncbi request reprint NCCN Task Force Report: breast cancer in the older woman
    Robert W Carlson
    J Natl Compr Canc Netw 6:S1-25; quiz S26-7. 2008
    ....
  42. ncbi request reprint HER2 testing in breast cancer: NCCN Task Force report and recommendations
    Robert W Carlson
    Stanford Hospital and Clinics
    J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006
    ..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed...
  43. ncbi request reprint Breast cancer in limited-resource countries: treatment and allocation of resources
    Alexandru Eniu
    Department of Breast Tumors, Oncology, Cancer Institute I Chiricuta, Cluj Napoca, Romania
    Breast J 12:S38-53. 2006
    ..Use of the scheme outlined here should help ministers of health, policymakers, administrators, and institutions in limited-resource settings plan, establish, and gradually expand breast cancer treatment services for their populations...
  44. ncbi request reprint Guidelines for improving breast health care in limited resource countries: the Breast Health Global Initiative
    Benjamin O Anderson
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, WA 98195, USA
    J Natl Compr Canc Netw 5:349-56. 2007
    ....
  45. ncbi request reprint Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  46. pmc Reliability of plasma carotenoid biomarkers and its relation to study power
    Wael K Al-Delaimy
    Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093 0901, USA
    Epidemiology 19:338-44. 2008
    ..We assessed reliability of plasma carotenoid levels over time and how it could influence study power through sample size and effect-size...
  47. ncbi request reprint Breast cancer risk reduction
    Therese B Bevers
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:676-701. 2007
  48. ncbi request reprint Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer
    Jane S Blake-Mortimer
    Department of Psychology, University of Adelaide, North Terrace, Adelaide, Australia
    Breast J 10:195-9. 2004
    ..Moreover, a reduced CTL count may be a mediator or marker of more rapid disease progression in metastatic breast cancer...
  49. pmc Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer
    Cheryl L Rock
    Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093 0901, USA
    Cancer Epidemiol Biomarkers Prev 17:614-20. 2008
    ....
  50. pmc Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial
    John P Pierce
    Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093 0901, USA
    JAMA 298:289-98. 2007
    ..Evidence is lacking that a dietary pattern high in vegetables, fruit, and fiber and low in total fat can influence breast cancer recurrence or survival...
  51. ncbi request reprint NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...